Antibody-mediated complement C3b/iC3b binding to group B streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border

Clinical and Vaccine Immunology

Volumn 22, Issue 3, 2015, Pages 319-326

  Herbert, Jenny ^a,g   Thomas, Stephen ^a   Brookes, Charlotte ^a   Turner, Claudia ^b,c,d   Turnerd, Paul ^b,c,d   Nostend, Francois ^b,c   Le Doare, Kirsty ^e,f   Hudson, Michael ^a   Heath, Paul T ^f   Gorringe, Andrew ^a   Taylor, Stephen ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

^d Angkor Hospital for Children   (Cambodia)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; BACTERIUM ANTIBODY; PROTEIN BINDING;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BACTERIUM CARRIER; BIRTH; BLOOD ANALYSIS; BLOOD SAMPLING; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GESTATIONAL AGE; HUMAN; MATERNAL AGE; MATERNAL BLOOD; MYANMAR; NEWBORN; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REFUGEE; SEROEPIDEMIOLOGY; STREPTOCOCCUS AGALACTIAE; THAILAND; UMBILICAL CORD BLOOD; EPIDEMIOLOGY; GROWTH, DEVELOPMENT AND AGING; HETEROZYGOTE; IMMUNOLOGY; METABOLISM; MOTHER; SEROTYPING; STATISTICAL ANALYSIS; STREPTOCOCCUS INFECTION;

ANTIBODIES, BACTERIAL; CARRIER STATE; COMPLEMENT C3B; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT, NEWBORN; MATCHED-PAIR ANALYSIS; MOTHERS; MYANMAR; PROTEIN BINDING; REFUGEES; SEROEPIDEMIOLOGIC STUDIES; SEROTYPING; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; THAILAND;

EID: 84923864119     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00803-14     Document Type: Article

References (46)

1. Lancefield RC, Hare R. 1935. The serological differentiation of pathogenic and non-pathogenic strains of hemolytic streptococci from parturient women. J Exp Med 61:335-349. http://dx.doi.org/10.1084/jem.61.3.335.
2. Libster R, Edwards KM, Levent F, Edwards MS, Rench MA, Castagnini LA, Cooper T, Sparks RC, Baker CJ, Shah PE. 2012. Long-term outcomes of group B streptococcal meningitis. Pediatrics 130:e8-e15. http://dx.doi.org/10.1542/peds.2011-3453.
3. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. 2001. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 323:533-536. http://dx.doi.org/10.1136/bmj.323.7312.533.
4. Moore MR, Schrag SJ, Schuchat A. 2003. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 3:201-213. http://dx.doi.org/10.1016/S1473-3099(03)00577-2.
5. Schrag SJ, Verani JR. 2013. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 31(Suppl 4):D20-D26. http://dx.doi.org/10.1016/j.vaccine.2012.11.056.
6. Jordan HT, Farley MM, Craig A, Mohle-Boetani J, Harrison LH, Petit S, Lynfield R, Thomas A, Zansky S, Gershman K, Albanese BA, Schaffner W, Schrag SJ. 2008. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 27:1057-1064. http://dx.doi.org/10.1097/INF.0b013e318180b3b9.
7. Guilbert J, Levy C, Cohen R, Delacourt C, Renolleau S, Flamant C. 2010. Late and ultra late onset streptococcus B meningitis: clinical and bacteriological data over 6 years in France. Acta Paediatr 99:47-51. http://dx.doi.org/10.1111/j.1651-2227.2010.02035.x.
8. Schuchat A, Oxtoby M, Cochi S, Sikes RK, Hightower A, Plikaytis B, Broome CV. 1990. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. J Infect Dis 162:672-677. http://dx.doi.org/10.1093/infdis/162.3.672.
9. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, O'Connell LAF, Cafferkey M, Verlander NQ, Nicoll A, McCartney AC. 2004. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363:292-294. http://dx.doi.org/10.1016/S0140-6736(03)15389-5.
10. Schroeder E-A, Petrou S, Balfour G, Edamma O, Heath PT. 2009. The economic costs of group B streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England. Eur J Health Econ 10:275-285. http://dx.doi.org/10.1007/s10198-008-0131-4.
11. Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB, Schrag SJ, Lynfield R. 2008. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008:727505. http://dx.doi.org/10.1155/2008/727505.
12. Edwards MS, Baker CJ, Kasper DL. 1979. Opsonic specificity of human antibody to the type III polysaccharide of group B streptococcus. J Infect Dis 140:1004-1008. http://dx.doi.org/10.1093/infdis/140.6.1004.
13. Brigtsen AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen H-K. 2002. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis 185:1277-1284. http://dx.doi.org/10.1086/340324.
14. Kasper DL, Paoletti LC, Wessels MR, Guttormsen HK, Carey VJ, Jennings HJ, Baker CJ. 1996. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 98:2308-2314. http://dx.doi.org/10.1172/JCI119042.
15. Guttormsen HK, Liu Y, Paoletti LC. 2008. Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells. Hum Vaccin 4:370-374. http://dx.doi.org/10.4161/hv.4.5.5988.
16. Guttormsen H-K, Mascuch SJ, West JC, Paoletti LC. 2009. A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B streptococcus. Hum Vaccin 5:461-466. http://dx.doi.org/10.4161/hv.8376.
17. Fabbrini M, Sammicheli C, Margarit I, Maione D, Grandi G, Giuliani MM, Mori E, Nuti S. 2012. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against group B streptococcus. J Immunol Methods 378:11-19. http://dx.doi.org/10.1016/j.jim.2012.01.011.
18. Turner C, Turner P, Po L, Maner N, De Zoysa A, Afshar B, Efstratiou A, Heath PT, Nosten F. 2012. Group B streptococcal carriage, serotype distribution and antibiotic susceptibilities in pregnant women at the time of delivery in a refugee population on the Thai-Myanmar border. BMC Infect Dis 12:34. http://dx.doi.org/10.1186/1471-2334-12-34.
19. Brookes C, Kuisma E, Alexander F, Allen L, Tipton T, Ram S, Gorringe A, Taylor S. 2013. Development of a large scale human complement source for use in bacterial immunoassays. J Immunol Methods 391:39-49. http://dx.doi.org/10.1016/j.jim.2013.02.007.
20. Reed GF, Meade BD, Steinhoff MC. 1995. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 96:600-603.
21. Baker CJ, Edwards MS, Kasper DL. 1981. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection. Pediatrics 68:544-549.
22. Baker CJ, Carey VJ, Rench MA, Edwards MS, Hillier SL, Kasper DL, Platt R. 2014. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 209:781-788. http://dx.doi.org/10.1093/infdis/jit549.
23. Baltimore RS, Kasper DL, Baker CJ, Goroff DK. 1977. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol 118:673-678.
24. Lehmann AK, Sornes S, Halstensen A. 2000. Phagocytosis: measurement by flow cytometry. J Immunol Methods 243:229-242. http://dx.doi.org/10.1016/S0022-1759(00)00237-4.
25. Michaelsen TE, Aase A. 2001. Antibody-induced opsonophagocytosis of serogroup B meningococci measured by flow cytometry. Methods Mol Med 66:331-337. http://dx.doi.org/10.1385/1-59259-148-5:331.
26. Aase A, Herstad TK, Merino S, Brandsdal KT, Berdal BP, Aleksandersen EM, Aaberge IS. 2007. Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway. Clin Vaccine Immunol 14:855-862. http://dx.doi.org/10.1128/CVI.00081-07.
27. Plested JS, Granoff DM. 2008. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 15:799-804. http://dx.doi.org/10.1128/CVI.00036-08.
28. Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Käyhty H, Väkeväinen M, Laferriere C, Wauters D, Nahm MH, Schinsky MF, Plikaytis BD, Carlone GM. 2003. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol 10:1019-1024. http://dx.doi.org/10.1128/CDLI.10.6.1019-1024.2003.
29. Burton RL, Nahm MH. 2012. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol 19:835-841. http://dx.doi.org/10.1128/CVI.00086-12.
30. Hu BT, Yu X, Jones TR, Kirch C, Harris S, Hildreth SW, Madore DV, Quataert SA. 2005. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin Diagn Lab Immunol 12:287-295. http://dx.doi.org/10.1128/CDLI.12.2.287-295.2005.
31. Aase A, Herstad TK, Merino S, Bolstad M, Sandbu S, Bakke H, Aaberge IS. 2011. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity. Clin Vaccine Immunol 18:1269-1274. http://dx.doi.org/10.1128/CVI.05067-11.
32. Fleck RA, Romero-Steiner S, Nahm MH. 2005. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol 12:19-27. http://dx.doi.org/10.1128/CDLI.12.1.19-27.2005.
33. Lewis LA, Ram S. 2014. Meningococcal disease and the complement system. Virulence 5:98-126. http://dx.doi.org/10.4161/viru.26515.
34. Hallström T, Riesbeck K. 2010. Haemophilus influenzae and the complement system. Trends Microbiol 18:258-265. http://dx.doi.org/10.1016/j.tim.2010.03.007.
35. Picard C, Puel A, Bustamante J, Ku C-L, Casanova J-L. 2003. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 3:451-459. http://dx.doi.org/10.1097/00130832-200312000-00006.
36. Hyams C, Trzcinski K, Camberlein E, Weinberger DM, Chimalapati S, Noursadeghi M, Lipsitch M, Brown JS. 2013. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. Infect Immun 81:354-363. http://dx.doi.org/10.1128/IAI.00862-12.
37. Hall MA, Edwards MS, Baker CJ. 1992. Complement and antibody participation in opsonophagocytosis of type IV and V group B streptococci. Infect Immun 60:5030-5035.
38. Baker CJ, Paoletti LC, Rench MA, Guttormsen H-K, Edwards MS, Kasper DL. 2004. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 189:1103-1112. http://dx.doi.org/10.1086/382193.
39. Edwards MS, Lane HJ, Hillier SL, Rench MA, Baker CJ. 2012. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 30:4123-4126. http://dx.doi.org/10.1016/j.vaccine.2012.04.048.
40. Manning SD, Wood S, Kasha K, Martin D, Rioux S, Brodeur B, Davies HD. 2006. Naturally occurring antibodies for the group B streptococcal surface immunogenic protein (Sip) in pregnant women and newborn babies. Vaccine 24:6905-6912. http://dx.doi.org/10.1016/j.vaccine.2006.06.020.
41. Tiskumara R, Fakharee SH, Liu CQ, Nuntnarumit P, Lui KM, Hammoud M, Lee JKF, Chow CB, Shenoi A, Halliday R, Isaacs D. 2009. Neonatal infections in Asia. Arch Dis Child Fetal Neonatal Ed 94:F144-F148. http://dx.doi.org/10.1136/adc.2008.139865.
42. Ippolito DL, James WA, Tinnemore D, Huang RR, Dehart MJ, Williams J, Wingerd MA, Demons ST. 2010. Group B streptococcus serotype prevalence in reproductive-age women at a tertiary care military medical center relative to global serotype distribution. BMC Infect Dis 10:336. http://dx.doi.org/10.1186/1471-2334-10-336.
43. Boyer KM, Papierniak CK, Gadzala CA, Parvin JD, Gotoff SP. 1984. Transplacental passage of IgG antibody to group B streptococcus serotype Ia. J Pediatr 104:618-620. http://dx.doi.org/10.1016/S0022-3476(84)80564-8.
44. Morell A, Sidiropoulos D, Herrmann U, Christensen KK, Christensen P, Prellner K, Fey H, Skvaril F. 1986. IgG subclasses and antibodies to group B streptococci, pneumococci, and tetanus toxoid in preterm neonates after intravenous infusion of immunoglobulin to the mothers. Pediatr Res 20:933-936. http://dx.doi.org/10.1203/00006450-198610000-00005.
45. Marchaim D, Efrati S, Melamed R, Gortzak-Uzan L, Riesenberg K, Zaidenstein R, Schlaeffer F. 2006. Clonal variability of group B streptococcus among different groups of carriers in southern Israel. Eur J Clin Microbiol Infect Dis 25:443-448. http://dx.doi.org/10.1007/s10096-006-0163-6.
46. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AKM, Cousens S, Heath PT. 2012. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379:547-556. http://dx.doi.org/10.1016/S0140-6736(11)61651-6.